Dapagliflozin in Type 2 Diabetes Patients in Routine Internal Medicine and Endocrinology Outpatient Clinical Care; a Retrospective Cohort Study From Turkey
Latest Information Update: 26 Mar 2022
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DAPA-TURK
- Sponsors AstraZeneca
Most Recent Events
- 28 Feb 2018 Status changed from recruiting to completed.
- 25 Jan 2018 New trial record